Predicting that investigatory referral will be the most severe bottleneck in the pathway, we explored the degree of mitigation achieved if 2WW CRC referrals with FIT ≥2, 10 or 150 μg Hb/g were prioritised out of the background delays. Here, GSTM1 is linked to colorectal carcinoma.